Therefore, unravelling novel effectors or modulators of PPARγ could be a promising approach to overcome this obstacle, especially concerning tumours harbouring activating mutations of RAS genes, which are primarily unresponsive to PPARγ activation. The gene discussed is PPARG; the disease is neoplasm.